NCT05634590View on ClinicalTrials.gov

The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

December 31, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Fruquintinib

4mg, orally, once daily, 3 weeks on/ 1 week off

DRUG

FOLFIRI

Irinotecan 180 mg/m2, and LV 400 mg/m2 followed by bolus 5-fluorouracil 400mg/m2 and a 46-48h continuous infusion 2400mg/m2 5-fluorouracil on day 1, q2w

DRUG

mFOLFOX6

Oxaliplatin 85 mg/m2, and LV 400 mg/m2 followed by bolus 5-fluorouracil 400mg/m2 and a 46-48h continuous infusion 2400mg/m2 5-fluorouracil on day 1, q2w

Trial Locations (1)

200032

Department of Colorectal Surgery Fudan University Shanghai Caner Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER